Craig W Hendrix
Overview
Explore the profile of Craig W Hendrix including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
202
Citations
7023
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bird H, Clarke W, Hendrix C, Dunn K, Huhn A
Am J Addict
. 2025 Feb;
PMID: 40018853
Background/objectives: The pharmacology of fentanyl and xylazine is not characterized in persons regularly exposed to illicit fentanyl. This case series presents individual-level urine pharmacokinetics of fentanyl, norfentanyl, and xylazine in...
2.
Diniz C, Abdul-Massih S, Bagia C, Giguere R, Rohan L, Wang L, et al.
J Acquir Immune Defic Syndr
. 2025 Jan;
PMID: 39847455
Background: Unprotected receptive anal intercourse (RAI) carries the highest sexual HIV transmission risk. The need for diverse pre-exposure prophylaxis (PrEP) options has encouraged the development of on-demand, topical PrEP products...
3.
Friedland B, Gundacker H, Achilles S, Chen B, Hoesley C, Richardson B, et al.
PLoS One
. 2025 Jan;
20(1):e0312957.
PMID: 39808648
End-user feedback early in product development is important for optimizing multipurpose prevention technologies for HIV and pregnancy prevention. We evaluated the acceptability of the 90-day dapivirine levonorgestrel ring (DPV-LNG ring)...
4.
Ho K, Hoesley C, Anderson P, Fernandez-Romero J, Friedland B, Kelly C, et al.
J Acquir Immune Defic Syndr
. 2025 Jan;
97(4):379-386.
PMID: 39808074
Background: On demand, topical PrEP is desired by those preferring episodic, nonsystemic PrEP. PC-1005 gel (MIV-150, zinc, and carrageenan) exhibits in vitro antiviral HIV-1, human papillomavirus (HPV), and herpes simplex...
5.
Delany-Moretlwe S, Hanscom B, Guo X, Nkabiito C, Mandima P, Nahirya P, et al.
J Int AIDS Soc
. 2025 Jan;
28(1):e26401.
PMID: 39748218
Introduction: Long-acting injectable cabotegravir (CAB-LA) for pre-exposure prophylaxis significantly reduced HIV acquisition in HPTN 084. We report on the safety and CAB-LA pharmacokinetics in pregnant women during the blinded period...
6.
Beesham I, Jaggernath M, Kriel Y, Hao J, Smith P, Haberer J, et al.
J Acquir Immune Defic Syndr
. 2024 Dec;
98(4):357-362.
PMID: 39705379
Background: Pregnant women are vulnerable to HIV acquisition. Oral HIV pre-exposure prophylaxis (PrEP) is safe and effective for use during pregnancy. We describe PrEP adherence among pregnant women using multiple...
7.
Marzinke M, Han K, Hanscom B, Guo X, Piwowar-Manning E, Hendrix C, et al.
Antimicrob Agents Chemother
. 2024 Sep;
68(11):e0099424.
PMID: 39311597
Clinical Trials: This study is registered with ClinicalTrials.gov as NCT03164564.
8.
Giguere R, Balan I, Lentz C, Dolezal C, Carballo-Dieguez A, Fuchs E, et al.
Sex Transm Infect
. 2024 Sep;
101(1):49-54.
PMID: 39237135
Objectives: DREAM-01 was an open label, dose-escalation and variable osmolarity study to identify a tenofovir HIV-prevention douche/enema that could achieve protective colon tissue cell concentrations and high acceptability. To assess...
9.
Kim H, Zhang L, Hendrix C, Haberer J, von Kleist M
CPT Pharmacometrics Syst Pharmacol
. 2024 Aug;
13(10):1693-1706.
PMID: 39164932
HIV prevention with pre-exposure prophylaxis (PrEP) constitutes a major pillar in fighting the ongoing epidemic. While daily oral PrEP adherence may be challenging, long-acting (LA-)PrEP in oral or implant formulations...
10.
Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial
Cooper S, Zhang S, Haines D, Mayer K, Amico K, Landovitz R, et al.
AIDS Behav
. 2024 Jul;
28(11):3710-3718.
PMID: 39083151
Adherence drives efficacy in PrEP clinical trials. We compared drug concentrations and self-reported adherence in HPTN069/ACTG5305, a double-blinded, randomized trial of the safety and tolerability of candidate PrEP regimens that...